Enlivex Therapeutics (NASDAQ:ENLV) Upgraded at Zacks Research

Enlivex Therapeutics (NASDAQ:ENLV) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

A number of other brokerages have also issued reports on ENLV. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Friday, June 26th. Wall Street Zen raised Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, HC Wainwright raised their price objective on Enlivex Therapeutics from $195.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, April 7th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $247.50.

Enlivex Therapeutics Trading Down 3.0%

NASDAQ:ENLV opened at $4.59 on Tuesday. The stock has a 50 day moving average of $9.11 and a two-hundred day moving average of $12.85. Enlivex Therapeutics has a 12 month low of $4.25 and a 12 month high of $31.50. The firm has a market cap of $77.25 million, a P/E ratio of -0.56 and a beta of 1.52.

Institutional Investors Weigh In On Enlivex Therapeutics

A number of large investors have recently made changes to their positions in ENLV. Virtu Financial LLC purchased a new position in Enlivex Therapeutics during the fourth quarter worth approximately $33,000. Invesco Ltd. purchased a new stake in Enlivex Therapeutics in the 4th quarter valued at $43,000. XTX Topco Ltd grew its holdings in Enlivex Therapeutics by 44.8% in the 4th quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock valued at $43,000 after buying an additional 19,132 shares in the last quarter. Jane Street Group LLC grew its holdings in Enlivex Therapeutics by 244.1% in the 4th quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock valued at $52,000 after buying an additional 52,553 shares in the last quarter. Finally, Susquehanna International Group LLP acquired a new stake in shares of Enlivex Therapeutics in the 3rd quarter worth $57,000. 1.02% of the stock is currently owned by hedge funds and other institutional investors.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.